7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Heart Failure D006333 36 associated lipids
Arthritis, Rheumatoid D001172 3 associated lipids
Osteitis D010000 10 associated lipids
Coronary Disease D003327 70 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Osteosarcoma D012516 50 associated lipids
Hip Fractures D006620 2 associated lipids
Osteolysis D010014 8 associated lipids
Hypothyroidism D007037 32 associated lipids
Osteoarthritis, Hip D015207 4 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Cundy T et al. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. 2002 Hum. Mol. Genet. pmid:12189164
Armstrong AP et al. A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. 2002 J. Biol. Chem. pmid:12185073
Ohmori H et al. Linkage and association analyses of the osteoprotegerin gene locus with human osteoporosis. 2002 J. Hum. Genet. pmid:12181640
Ulrich-Vinther M et al. Recombinant adeno-associated virus-mediated osteoprotegerin gene therapy inhibits wear debris-induced osteolysis. 2002 J Bone Joint Surg Am pmid:12177271
Ragab AA et al. Cytokines synergistically induce osteoclast differentiation: support by immortalized or normal calvarial cells. 2002 Am. J. Physiol., Cell Physiol. pmid:12176725
Uemura H et al. Serum osteoprotegerin/osteoclastogenesis-inhibitory factor during pregnancy and lactation and the relationship with calcium-regulating hormones and bone turnover markers. 2002 J. Endocrinol. pmid:12176675
Geoffroy V et al. High bone resorption in adult aging transgenic mice overexpressing cbfa1/runx2 in cells of the osteoblastic lineage. 2002 Mol. Cell. Biol. pmid:12167715
Lorget F et al. Lactoferrin reduces in vitro osteoclast differentiation and resorbing activity. 2002 Biochem. Biophys. Res. Commun. pmid:12163011
Mundy GR Metastasis to bone: causes, consequences and therapeutic opportunities. 2002 Nat. Rev. Cancer pmid:12154351
Hofbauer LC et al. Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells. 2002 Eur. J. Endocrinol. pmid:12153751
Chen XW et al. Isoflavones regulate interleukin-6 and osteoprotegerin synthesis during osteoblast cell differentiation via an estrogen-receptor-dependent pathway. 2002 Biochem. Biophys. Res. Commun. pmid:12150965
Grisar J et al. Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. 2002 J. Rheumatol. pmid:12136902
Petersson M et al. Oxytocin stimulates proliferation of human osteoblast-like cells. 2002 Peptides pmid:12126740
Sakata M et al. Osteoprotegerin levels increased by interleukin-1beta in human periodontal ligament cells are suppressed through prostaglandin E(2) synthesized de novo. 2002 Cytokine pmid:12126649
Campagnuolo G et al. Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis. 2002 Arthritis Rheum. pmid:12124878
Ziolkowska M et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. 2002 Arthritis Rheum. pmid:12124857
Krane SM Genetic control of bone remodeling--insights from a rare disease. 2002 N. Engl. J. Med. pmid:12124412
Whyte MP et al. Osteoprotegerin deficiency and juvenile Paget's disease. 2002 N. Engl. J. Med. pmid:12124406
Biskobing DM et al. Novel therapeutic options for osteoporosis. 2002 Curr Opin Rheumatol pmid:12118183
Lipton A et al. Serum osteoprotegerin levels in healthy controls and cancer patients. 2002 Clin. Cancer Res. pmid:12114435
Shioi A et al. Induction of bone-type alkaline phosphatase in human vascular smooth muscle cells: roles of tumor necrosis factor-alpha and oncostatin M derived from macrophages. 2002 Circ. Res. pmid:12114316
Lee SK and Lorenzo JA Regulation of receptor activator of nuclear factor-kappa B ligand and osteoprotegerin mRNA expression by parathyroid hormone is predominantly mediated by the protein kinase a pathway in murine bone marrow cultures. 2002 Bone pmid:12110442
Katagiri T and Takahashi N Regulatory mechanisms of osteoblast and osteoclast differentiation. 2002 Oral Dis pmid:12108759
Saidenberg Kermanac'h N et al. Osteoprotegerin and inflammation. 2002 Apr-Jun Eur. Cytokine Netw. pmid:12101070
Zhang J et al. Osteoprotegerin abrogates chronic alcohol ingestion-induced bone loss in mice. 2002 J. Bone Miner. Res. pmid:12096839
Langdahl BL et al. Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures. 2002 J. Bone Miner. Res. pmid:12096838
Koyama H et al. Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation. 2002 J. Bone Miner. Res. pmid:12096835
Zou W and Bar-Shavit Z Dual modulation of osteoclast differentiation by lipopolysaccharide. 2002 J. Bone Miner. Res. pmid:12096834
Xing L et al. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. 2002 J. Bone Miner. Res. pmid:12096833
Price PA et al. Bone origin of the serum complex of calcium, phosphate, fetuin, and matrix Gla protein: biochemical evidence for the cancellous bone-remodeling compartment. 2002 J. Bone Miner. Res. pmid:12096831
Khosla S et al. Correlates of osteoprotegerin levels in women and men. 2002 Osteoporos Int pmid:12086350
Kim YH et al. Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression. 2002 Exp. Mol. Med. pmid:12085990
Wynne F et al. Investigation of the genetic influence of the OPG, VDR (Fok1), and COLIA1 Sp1 polymorphisms on BMD in the Irish population. 2002 Calcif. Tissue Int. pmid:12073153
Nakamura H et al. Localization of osteoprotegerin (OPG) on bone surfaces and cement lines in rat tibia. 2002 J. Histochem. Cytochem. pmid:12070273
Zhang J et al. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. 2002 FEBS Lett. pmid:12067713
Fu M et al. Activation of peroxisome proliferator-activated receptor gamma inhibits osteoprotegerin gene expression in human aortic smooth muscle cells. 2002 Biochem. Biophys. Res. Commun. pmid:12056809
Penno H et al. Osteoprotegerin secretion from prostate cancer is stimulated by cytokines, in vitro. 2002 Biochem. Biophys. Res. Commun. pmid:12054622
Wittrant Y et al. Osteoprotegerin differentially regulates protease expression in osteoclast cultures. 2002 Biochem. Biophys. Res. Commun. pmid:12054560
Brändström H et al. A single nucleotide polymorphism in the promoter region of the human gene for osteoprotegerin is related to vascular morphology and function. 2002 Biochem. Biophys. Res. Commun. pmid:12054556
Sasaki N et al. Changes in osteoprotegerin and markers of bone metabolism during glucocorticoid treatment in patients with chronic glomerulonephritis. 2002 Bone pmid:12052453
Ueland T et al. Effects of 12 months of GH treatment on cortical and trabecular bone content of IGFs and OPG in adults with acquired GH deficiency: a double-blind, randomized, placebo-controlled study. 2002 J. Clin. Endocrinol. Metab. pmid:12050246
Lossdörfer S et al. Immunohistochemical localization of receptor activator of nuclear factor kappaB (RANK) and its ligand (RANKL) in human deciduous teeth. 2002 Calcif. Tissue Int. pmid:12043011
Treuheit MJ et al. Inverse relationship of protein concentration and aggregation. 2002 Pharm. Res. pmid:12033388
Li X et al. Prostaglandin receptor EP2 mediates PGE2 stimulated hypercalcemia in mice in vivo. 2002 Prostaglandins Other Lipid Mediat. pmid:12013525
Granchi D et al. Bone cement extracts modulate the osteoprotegerin/osteoprotegerin-ligand expression in MG63 osteoblast-like cells. 2002 Biomaterials pmid:12013183
Jiang Y et al. Bacteria induce osteoclastogenesis via an osteoblast-independent pathway. 2002 Infect. Immun. pmid:12011008
Iida-Klein A et al. Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice. 2002 J. Bone Miner. Res. pmid:12009011
Ono K et al. Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines. 2002 J. Bone Miner. Res. pmid:12009007
Bosshart H Expression of survival receptors in Hodgkin disease cell lines. 2002 Blood pmid:12001908
de Hooge AS et al. Adenoviral transfer of murine oncostatin M elicits periosteal bone apposition in knee joints of mice, despite synovial inflammation and up-regulated expression of interleukin-6 and receptor activator of nuclear factor-kappa B ligand. 2002 Am. J. Pathol. pmid:12000725
Gruber R et al. Platelet-released supernatants stimulate formation of osteoclast-like cells through a prostaglandin/RANKL-dependent mechanism. 2002 Bone pmid:11996911
Corey E et al. Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. 2002 Prostate pmid:11992617
Evdokiou A et al. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. 2002 Int. J. Cancer pmid:11992538
Hasegawa T et al. Human periodontal ligament cells derived from deciduous teeth induce osteoclastogenesis in vitro. 2002 Tissue Cell pmid:11989970
Koshihara Y [Recent progress of bone cell culture system (review)]. 2002 Nippon Rinsho pmid:11979973
Tsuda E [Osteoclastogenesis inhibitory factor (OCIF)/OPG (a novel therapeutic candidate for the treatment of metabolic bone diseases)]. 2002 Nippon Rinsho pmid:11979969
Udagawa N and Takahashi N [Possible role of receptor activator of NF-kappa B ligand(RANKL) in osteoclast differentiation and function]. 2002 Nippon Rinsho pmid:11979968
Inoue D [Recent advances in research of bone resorption]. 2002 Nippon Rinsho pmid:11979946
Suzuki Y et al. [Bone destruction and bone loss in rheumatoid arthritis--mechanism, prevention and treatment]. 2002 Nippon Rinsho pmid:11979937
Inoue D and Matsumoto T [Recent advances in basic research of bone metabolism]. 2002 Nippon Rinsho pmid:11979916
Bateman TA and Countryman S Osteoprotegerin and bone loss associated with spaceflight. 2002 Drug Discov. Today pmid:11965392
Ariyasu T et al. Trehalose augments osteoprotegerin production in the FHs74Int human intestinal epithelial cell line. 2002 In Vitro Cell. Dev. Biol. Anim. pmid:11963965
Schoppet M et al. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. 2002 Arterioscler. Thromb. Vasc. Biol. pmid:11950689
Jain RG and Lenhard JM Select HIV protease inhibitors alter bone and fat metabolism ex vivo. 2002 J. Biol. Chem. pmid:11937496
Li X et al. Effects of prostaglandin E2 on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice. 2002 Bone pmid:11934647
Kanematsu M et al. Vector-averaged gravity regulates gene expression of receptor activator of NF-kappaB (RANK) ligand and osteoprotegerin in bone marrow stromal cells via cyclic AMP/protein kinase A pathway. 2002 Bone pmid:11934645
Khosla S et al. Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. 2002 J. Clin. Endocrinol. Metab. pmid:11932280
Redlich K et al. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. 2002 Arthritis Rheum. pmid:11920416
Oshiro T et al. Osteoclast induction in periodontal tissue during experimental movement of incisors in osteoprotegerin-deficient mice. 2002 Anat. Rec. pmid:11920384
Roux S et al. RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma. 2002 Br. J. Haematol. pmid:11918537
Goater JJ et al. Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis. 2002 J. Orthop. Res. pmid:11918293
Mori H et al. RANK ligand, RANK, and OPG expression in type II collagen-induced arthritis mouse. 2002 Histochem. Cell Biol. pmid:11914926
Holen I et al. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. 2002 Cancer Res. pmid:11912131
Feige U Osteoprotegerin. 2001 Ann. Rheum. Dis. pmid:11890662
Haas M et al. Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. 2002 Am. J. Kidney Dis. pmid:11877577
Kazama JJ et al. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. 2002 Am. J. Kidney Dis. pmid:11877571
Faucheux C et al. Nuclear localization of type I parathyroid hormone/parathyroid hormone-related protein receptors in deer antler osteoclasts: evidence for parathyroid hormone-related protein and receptor activator of NF-kappaB-dependent effects on osteoclast formation in regenerating mammalian bone. 2002 J. Bone Miner. Res. pmid:11874237
Green EA et al. Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. 2002 Immunity pmid:11869680
Roux S et al. RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. 2002 Am. J. Clin. Pathol. pmid:11863217
Theill LE et al. RANK-L and RANK: T cells, bone loss, and mammalian evolution. 2002 Annu. Rev. Immunol. pmid:11861618
Romas E et al. Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. 2002 Bone pmid:11856640
Viereck V et al. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. 2002 Biochem. Biophys. Res. Commun. pmid:11855844
Hofbauer LC and Kühne CA Cytokine inhibition: a new therapeutic avenue for skeletal diseases. 2002 Drug Discov. Today pmid:11854049
Scatena M and Giachelli C The alpha(v)beta3 integrin, NF-kappaB, osteoprotegerin endothelial cell survival pathway. Potential role in angiogenesis. 2002 Trends Cardiovasc. Med. pmid:11852256
Wise GE et al. Inhibition of osteoclastogenesis by the secretion of osteoprotegerin in vitro by rat dental follicle cells and its implications for tooth eruption. 2002 Arch. Oral Biol. pmid:11839361
Viereck V et al. Phytoestrogen genistein stimulates the production of osteoprotegerin by human trabecular osteoblasts. 2002 J. Cell. Biochem. pmid:11835398
Coen G et al. Serum osteoprotegerin and renal osteodystrophy. 2002 Nephrol. Dial. Transplant. pmid:11812872
Holloway WR et al. Leptin inhibits osteoclast generation. 2002 J. Bone Miner. Res. pmid:11811550
Childs LM et al. In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. 2002 J. Bone Miner. Res. pmid:11811549
Mochizuki S et al. Osteoclastogenesis inhibitory factor/osteoprotegerin ameliorates the decrease in both bone mineral density and bone strength in immobilized rats. 2002 J. Bone Miner. Metab. pmid:11810411
Mizukami J et al. Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. 2002 Mol. Cell. Biol. pmid:11809792
Ramalho AC et al. Effect of oestradiol on cytokine production in immortalized human marrow stromal cell lines. 2001 Cytokine pmid:11792122
Nosaka K et al. Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. 2002 Blood pmid:11781248
Yang X et al. Protein Kinase C is a mediator of the synthesis and secretion of osteoprotegerin in osteoblast-like cells. 2002 Biochem. Biophys. Res. Commun. pmid:11779130
Whyte MP and Hughes AE Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. 2002 J. Bone Miner. Res. pmid:11771666
Komuro H et al. The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage. 2001 Arthritis Rheum. pmid:11762937
Chung H et al. Deflazacort increases osteoclast formation in mouse bone marrow culture and the ratio of RANKL/OPG mRNA expression in marrow stromal cells. 2001 J. Korean Med. Sci. pmid:11748360
Cao Y et al. IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. 2001 Cell pmid:11747812
Halladay DL et al. Identification of signal transduction pathways and promoter sequences that mediate parathyroid hormone 1-38 inhibition of osteoprotegerin gene expression. 2001 J. Cell. Biochem. pmid:11746511
Dhore CR et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. 2001 Arterioscler. Thromb. Vasc. Biol. pmid:11742876

Table of Content